

## A multidisciplinary forum: How can we improve management of hormone-sensitive prostate cancer?

Industry session by FERRING PHARMACEUTICALS

**Sunday, 26 March**  
**17:45 - 19:15**

**Location:** Room Vienna, North Hall (Level 1)

**Chair:** A. Briganti, Milan (IT)

### **Aims and objectives of this session**

- A multidisciplinary panel of clinicians will share best practice around the current place of androgen deprivation therapy (ADT) in the treatment of hormone-sensitive prostate cancer across the different stages of the disease
  - – To include treatment adjuvant to surgery and radiation
  - – In combination with chemotherapy
- Highlight the differences in mechanism of action and compare efficacy and safety profiles of different ADT agents
- Discuss future directions in hormonal treatment of prostate cancer

17:45 - 17:50

### **Welcome and introduction**

A. Briganti, Milan (IT)

17:50 - 18:07

### **The role of (neo) adjuvant hormonal treatment with surgery for localised high-risk and locally-advanced prostate cancer**

A. Briganti, Milan (IT)

18:07 - 18:24

### **Combining radiation therapy and androgen deprivation for intermediate- and high-risk prostate cancer - A critical review**

H. Payne, London (GB)

18:24 - 18:41

### **Hormonal therapies are not all the same: Role of antagonists vs agonists**

A.S. Merseburger, Lübeck (DE)

18:41 - 18:58

### **ADT & cardiovascular risks: Current evidence and future research**

D.J. Rosario, Sheffield (GB)

18:58 - 19:15

### **Panel discussion on future treatment directions**